Kevin Fitzgerald - Alnylam Pharmaceuticals Senior Vice President Chief Scientific Officer
| ALNY Stock | USD 147.36 4.05 2.83% |
President
Dr. Kevin Fitzgerald is Senior Vice President, Chief Scientific Officer of the company. Dr. Fitzgerald will be responsible for the strategic direction and oversight of Alnylam discovery engine. He has over 20 years of experience in the context of small molecule and oligonucleotide drug discovery since 2019.
| Age | 55 |
| Tenure | 5 years |
| Address | 675 West Kendall Street, Cambridge, MA, United States, 02142 |
| Phone | 617 551 8200 |
| Web | https://www.alnylam.com |
Alnylam Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.0478) % which means that it has lost $0.0478 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (15.0066) %, meaning that it created substantial loss on money invested by shareholders. Alnylam Pharmaceuticals' management efficiency ratios could be used to measure how well Alnylam Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to rise to 2.10 in 2024, whereas Return On Tangible Assets are likely to drop (0.15) in 2024. At this time, Alnylam Pharmaceuticals' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 889.5 M in 2024, despite the fact that Non Currrent Assets Other are likely to grow to (3.4 B).Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Marc Schneebaum | Madrigal Pharmaceuticals | 64 | |
| Victoria Brown | Apellis Pharmaceuticals | 44 | |
| Eric Siegel | Incyte | 51 | |
| Henry Fuchs | Biomarin Pharmaceutical | 60 | |
| Tracey McCain | Blueprint Medicines Corp | 50 | |
| Michael Benkowitz | United Therapeutics | 52 | |
| Wendy Rieder | Madrigal Pharmaceuticals | 46 | |
| Gisela Schwab | Exelixis | 61 | |
| Alison Armour | Halozyme Therapeutics | 53 | |
| Jayson Dallas | Ultragenyx | 49 | |
| Paul Mahon | United Therapeutics | 54 | |
| Ahmad Sadr | Apellis Pharmaceuticals | 44 | |
| John Pinion | Ultragenyx | 52 | |
| David Gryska | Incyte | 61 | |
| Pamela Simonton | Exelixis | 63 | |
| Fouad MD | Blueprint Medicines Corp | 55 | |
| Dimitrios Chondros | Halozyme Therapeutics | 53 | |
| Lisa Hayes | ProQR Therapeutics BV | N/A | |
| Nicole Perry | Apellis Pharmaceuticals | 53 | |
| David Zaccardelli | United Therapeutics | 50 | |
| Suma Krishnan | Krystal Biotech | 59 | |
Management Performance
| Return On Equity | -15.01 | ||||
| Return On Asset | -0.0478 |
Alnylam Pharmaceuticals Leadership Team
Elected by the shareholders, the Alnylam Pharmaceuticals' board of directors comprises two types of representatives: Alnylam Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Alnylam. The board's role is to monitor Alnylam Pharmaceuticals' management team and ensure that shareholders' interests are well served. Alnylam Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Alnylam Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Alan Eisenberg, Vice President - Global Public Policy and Government Relations | ||
| Michael Bonney, Director | ||
| Saraswathy Nochur, Equity Diversity | ||
| Indrani JD, Executive Secretary | ||
| Kevin Fitzgerald, Senior Vice President Chief Scientific Officer | ||
| Masako Nakamura, Senior Vice President - Head of Asia | ||
| Pushkal MD, Chief Affairs | ||
| Dennis Ausiello, Independent Director | ||
| John Clarke, Founder, Director and Chairman of Nominating and Corporate Governance Committee | ||
| John Maraganore, CEO, Director | ||
| Phillip Sharp, Independent Director | ||
| Tolga MBA, Executive Officer | ||
| Margaret Hamburg, Director | ||
| MBChB MBA, CEO Director | ||
| Amy Schulman, Director | ||
| Evan MBA, Chief Officer | ||
| Peter Smith, Senior Vice President - Early Development | ||
| Yvonne Greenstreet, COO, Executive Vice President | ||
| DavidAlexandre Gros, Senior Vice President Chief Business Officer | ||
| Manmeet Soni, CFO, Senior Vice President Principal Financial Officer | ||
| Steven Paul, Independent Director | ||
| Laurie Keating, Sr. VP, General Counsel and Secretary | ||
| Evan Lippman, Chief Officer | ||
| Akshay Vaishnaw, Executive Vice President Chief Medical Officer | ||
| Piyush JD, Chief Officer | ||
| Pushkal Garg, Senior Vice President - Clinical Development | ||
| Marsha Fanucci, Independent Director | ||
| Colleen Reitan, Director | ||
| Kevin Starr, Independent Director | ||
| Alfred Boyle, Chief Officer | ||
| Timothy Maines, Chief Officer | ||
| Michael BA, Ex Chairman | ||
| Jing Marantz, Senior Vice President Head of Medical Affairs | ||
| Muthiah Manoharan, Senior Board | ||
| Christine Lindenboom, Senior Communications | ||
| Theresa Heggie, Senior Vice President Head of Europe and Canada | ||
| MBA MBA, CEO Director | ||
| Barry Greene, Pres and COO | ||
| Michael Mason, VP of Fin. and Treasurer | ||
| Kelley Boucher, Chief Human Resource Officer, Senior Vice President | ||
| Jeffrey MBA, CFO VP | ||
| Paul Schimmel, Independent Director | ||
| David Pyott, Director |
Alnylam Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Alnylam Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -15.01 | ||||
| Return On Asset | -0.0478 | ||||
| Profit Margin | (0.24) % | ||||
| Operating Margin | (0.26) % | ||||
| Current Valuation | 18.29 B | ||||
| Shares Outstanding | 126.45 M | ||||
| Shares Owned By Insiders | 0.41 % | ||||
| Shares Owned By Institutions | 95.01 % | ||||
| Number Of Shares Shorted | 2.5 M | ||||
| Price To Earning | (22.92) X |
Pair Trading with Alnylam Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Alnylam Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Alnylam Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Alnylam Stock
| 0.75 | DVAX | Dynavax Technologies Financial Report 7th of May 2024 | PairCorr |
Moving against Alnylam Stock
| 0.75 | HCM | HUTCHMED DRC | PairCorr |
| 0.54 | BHC | Bausch Health Companies Financial Report 2nd of May 2024 | PairCorr |
| 0.5 | DRRX | Durect Earnings Call This Week | PairCorr |
| 0.41 | EBS | Emergent Biosolutions Financial Report 14th of May 2024 | PairCorr |
The ability to find closely correlated positions to Alnylam Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Alnylam Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Alnylam Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Alnylam Pharmaceuticals to buy it.
The correlation of Alnylam Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Alnylam Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Alnylam Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Alnylam Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alnylam Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Alnylam Stock please use our How to Invest in Alnylam Pharmaceuticals guide.You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Complementary Tools for Alnylam Stock analysis
When running Alnylam Pharmaceuticals' price analysis, check to measure Alnylam Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alnylam Pharmaceuticals is operating at the current time. Most of Alnylam Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Alnylam Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alnylam Pharmaceuticals' price. Additionally, you may evaluate how the addition of Alnylam Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets |
Is Alnylam Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alnylam Pharmaceuticals. If investors know Alnylam will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alnylam Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.53) | Revenue Per Share 14.637 | Quarterly Revenue Growth 0.312 | Return On Assets (0.05) | Return On Equity (15.01) |
The market value of Alnylam Pharmaceuticals is measured differently than its book value, which is the value of Alnylam that is recorded on the company's balance sheet. Investors also form their own opinion of Alnylam Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Alnylam Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alnylam Pharmaceuticals' market value can be influenced by many factors that don't directly affect Alnylam Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alnylam Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Alnylam Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alnylam Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.